Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04830137 · ClinicalTrials.gov registry record · Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

A Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Nurix Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
248
Enrollment target
16
Study locations

NCT04830137 is a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Nurix Therapeutics. The registered enrollment target is 248 participants, above the 183-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (36% higher). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04830137, a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Nurix Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
248 participants
Enrollment target
16
Study locations

Study Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

Conditions Studied

Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) Diffuse Large B Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Mantle Cell Lymphoma (MCL) Primary Central Nervous System Lymphoma (PCNSL) Marginal Zone Lymphoma (MZL) Waldenstrom Macroglobulinemia (WM)

Interventions

  • DRUG NX-2127

Study Locations (16)

California

  • City of Hope - Duarte
  • University of California Irvine - Orange
  • University of California San Francisco Medical Center - San Francisco

Florida

  • Mount Sinai Comprehensive Cancer Center - Miami Beach
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Sarasota

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • OSU Wexner Medical Center - Columbus

Texas

  • Baylor University Medical Center - Dallas
  • MD Anderson Cancer Center - Houston

Colorado

  • Sarah Cannon Research Institute at Colorado Blood Cancer Institute - Denver

Illinois

  • The University of Chicago Medical Center - Chicago

Maryland

  • National Institutes of Health Clinical Center - Bethesda

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 248 participants
Start Date 2021-05-05
Est. Completion 2027-05
Phase Phase 1

Sponsor

Nurix Therapeutics

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04830137

The ClinicalTrials.gov registry entry for NCT04830137 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 183-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (36% higher). The listed sponsor is Nurix Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which NX-2127 is the first listed.

NCT04830137 reports 16 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT04830137 about?

NCT04830137 is a clinical study titled "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

What is the current status of trial NCT04830137?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2021-05-05. Estimated completion is 2027-05.

What conditions does trial NCT04830137 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL).

What interventions are being tested in trial NCT04830137?

The interventions under investigation include: NX-2127 (DRUG).

Who is sponsoring clinical trial NCT04830137?

This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04830137 being conducted?

This trial has 16 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia (CLL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia (CLL)

All registered trials for this condition

Small Lymphocytic Lymphoma (SLL)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.